VLON insider filings
Vallon Pharmaceuticals, Inc. — 20 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-12-15. Screen VLON transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for VLON between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Vallon Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-12-15 | 4 | Thorell Marella — Director | Other (J): 28,517 @ $0 | EDGAR |
| 2022-07-06 | 4 | Thorell Marella — Director | Grant/award (A): 38,023 @ $0 | EDGAR |
| 2022-06-10 | 4 | Ammer Richard — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Thorell Marella — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Payne Joseph E — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2022-03-09 | 4 | Chhabra Meenu — Director | Grant/award (A): 15,000 (derivative) @ $7.67 | EDGAR |
| 2022-03-01 | 4 | Baker David Charles — Chief Executive Officer, Director | Grant/award (A): 61,000 (derivative) @ $5.63 | EDGAR |
| 2022-03-01 | 4 | Kelly Leanne M. — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $5.63 | EDGAR |
| 2021-06-04 | 4 | Kelly Leanne M. — Chief Financial Officer | Purchase (P): 3,657 @ $4 · Purchase (P): 1,085 @ $4.05 · Purchase (P): 1,508 @ $4.08 | EDGAR |
| 2021-05-27 | 4 | Payne Joseph E — Director | Purchase (P): 10,700 @ $3.85 · Purchase (P): 6,800 @ $4.50 | EDGAR |
| 2021-05-18 | 4 | Baker David Charles — Chief Executive Officer, Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Ammer Richard — Director | Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 10,204 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Levi Ofir — Director | Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Toren Penny — SVP, Regul Affairs & Prog Mgmt | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Payne Joseph E — Director | Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 14,286 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Kelly Leanne M. — Chief Financial Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2021-02-12 | 4 | Ammer Richard — Director | Other (J): 47,063 @ $6.40 | EDGAR |
| 2021-02-12 | 4 | SALMON Pharma GmbH — 10% owner | Other (J): 47,063 @ $6.40 | EDGAR |
| 2021-02-12 | 4 | Thorell Marella — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-02-12 | 4 | Baker David Charles — Chief Executive Officer, Director | Other (J): 7,843 @ $6.40 · Purchase (P): 1,000 @ $8 | EDGAR |
Recent 8-K events — Vallon Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-21 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-16 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-01-15 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VLON returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs